Evaluation of Soluble CD25 as a Marker in Chronic Liver Diseases in Children | ||||
| Egyptian Journal of Medical Microbiology | ||||
| Volume 31, Issue 4, October 2022, Page 157-164 PDF (342.94 K) | ||||
| Document Type: New and original researches in the field of Microbiology. | ||||
| DOI: 10.21608/ejmm.2022.265442 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Shaimaa Abdel Tawab Mohammed1; osamaa Ezzat Botrous2; Mahmoud Abd Elkhalek3; Mostafa Saleh Abdel-Motaleb  4
| ||||
| 1specialist of pediatrics Beni-Suef Specialized Hospital | ||||
| 2Professor of Pediatrics Faculty of Medicine , Beni-Suef University | ||||
| 3Department of Pediatrics, Faculty of medicine Beni-Suef University | ||||
| 4Department of Medical Microbiology & Immunology, Faculty of Medicine – Beni-Suef University. | ||||
| Abstract | ||||
| Background: Based on the crucial pathogenic role of inflammation for the progress of hepatic disorders, we hypothesized that the soluble interleukin-2 receptor (sIL-2R, also known as s CD25) would be a sign of inflammatory cell activation and disease severity in people with chronic liver diseases (CLD). Objectives: Our study aimed to evaluate soluble CD25 as a possible indicator of immune cell activation in CLD and acute liver diseases in a group of pediatric Egyptian patients. Methodology: This study was a case control study that included 120 children presented with liver disease aged 2 month-15 years and 60 unrelated healthy controls. The patients were recruited from Pediatric Hepatology Clinic, Beni- Suef University. All children were subjected to history taking, full clinical examination, laboratory tests (CBC, GGT, ALP, AST, ALT, serum albumin, PT, PC, PTT, INR and Soluble CD25 level). Results: Children with chronic liver disease with fibrosis had serum sIL-2R levels that were considerably lower (19.16±12.33 ng/ml) than children with acute liver disease (27.65±14.19 ng/ml) (p=0.036) and controls (29.23±13.20 ng/ml) (p=0.008). Children with chronic liver disease without fibrosis had a mean CD25 level of (23.33±16.31 ng/ml), which was not statistically different from other groups (p=0.655). Conclusions: further research is needed to clarify the role of sCD25 as an immunological marker to predict the occurrence of liver fibrosis in pediatric hepatic disorders and to differentiate between acute & chronic hepatic disorders. | ||||
| Keywords | ||||
| Soluble CD25; immunological marker; chronic Liver disease; Liver fibrosis; Interleukin-2 receptor | ||||
|
Statistics Article View: 175 PDF Download: 140 |
||||
